Completing data — refresh the page later to see the latest
175131-60-9CCN(CC)C(=O)[C@@]1(c2ccccc2)C[C@H]1CN.ClXNCDYJFPRPDERF-NQQJLSKUSA-NSee also: Levomilnacipran (has active moiety); Milnacipran Hydrochloride (annotation moved to).
175131-60-9FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Danger
H301 (50%): Toxic if swallowed [Danger Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P273, P280, P301+P316, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
LEVOMILNACIPRAN HYDROCHLORIDE
Serotonin Uptake Inhibitors [MoA]; Serotonin and Norepinephrine Reuptake Inhibitor [EPC]; Norepinephrine Uptake Inhibitors [MoA]
Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.
Drugs that selectively block or suppress the plasma membrane transport of SEROTONIN and NORADRENALINE into axon terminals and are used as ANTIDEPRESSIVE AGENTS.
DescriptionLevomilnacipran (Fetzima®) is a dual serotonin–norepinephrine reuptake inhibitor (SNRI) approved by the FDA in 2013 for the treatment of major depressive disorders (MDD). Levomilnacipran is the most active enantiomer of the racemate Milnacipran, which is currently used to treat pain associated with fibromyalgia. The drug was developed by Forest Laboratories and the Pierre Fabre group.
UsesThe (1S-cis)-enatiomer of Milnacipran (M344600). A selective norepinephrine and serotonin reuptake inhibitor approved for the management of fibromyalgia.
UsesThe S-enatiomer of Milnacipran (M344600).
DTXSID801026201CHEMBL2105732